You just read:

Labrys Biologics Secures $31 Million Series A Financing from Venture Capital Firms; Acquires Phase 2 Ready Antibody for Chronic Migraine from Pfizer

News provided by

Labrys Biologics Inc.

Jan 03, 2013, 07:30 EST